BTIG keeps a Buy rating on Mersana Therapeutics (MRSN) with a $6 price target after the company presented data for Emi-Le from the Phase I study in solid tumors. The firm views the data favorably with a 23% overall response rate and a “differentiated” safety profile, exceeding its base case and approaching its bull case scenario. BTIG says the selloff in the stock post the data is overdone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics Gains Fast Track for Emi-Le
- Mersana Therapeutics: FDA grants additional Fast Track designation to XMT-1660
- Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial
- Mersana Therapeutics transferred with Buy rating at Citi
- Mersana Therapeutics Reports Q3 2024 Financial Results